Search

Your search keyword '"Natsumeda, Yutaka"' showing total 116 results
Start Over Author "Natsumeda, Yutaka"
116 results on '"Natsumeda, Yutaka"'

8. Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial

Author

Higurashi Takuma, Hosono Kunihiro, Endo Hiroki, Takahashi Hirokazu, Iida Hiroshi, Uchiyama Takashi, Ezuka Akiko, Uchiyama Shiori, Yamada Eiji, Ohkubo Hidenori, Sakai Eiji, Maeda Shin, Morita Satoshi, Natsumeda Yutaka, Nagase Hajime, and Nakajima Atsushi

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Colorectal cancer (CRC) is one of the most commonly occurring neoplasms and a leading cause of cancer death worldwide, and new preventive strategies are needed to lower the burden of this disease. Eicosapentaenoic acid (EPA), the omega-3 polyunsaturated fatty acid that is widely used in the treatment of hyperlipidemia and prevention of cardiovascular disease, has recently been suggested to have a suppressive effect on tumorigenesis and cancer cell growth. In CRC chemoprevention trials, in general, the incidence of polyps or of the cancer itself is set as the study endpoint. Although the incidence rate of CRC would be the most reliable endpoint, use of this endpoint would be unsuitable for chemoprevention trials, because of the relatively low occurrence rate of CRC in the general population and the long-term observation period that it would necessitate. Moreover, there is an ethical problem in conducting long-term trials to determine whether a test drug might be effective or harmful. Aberrant crypt foci (ACF), defined as lesions containing crypts that are larger in diameter and stain more darkly with methylene blue than normal crypts, are considered as a reliable surrogate biomarker of CRC. Thus, we devised a prospective randomized controlled trial as a preliminary study prior to a CRC chemoprevention trial to evaluate the chemopreventive effect of EPA against colorectal ACF formation and the safety of this drug, in patients scheduled for polypectomy. Methods This study is a multicenter, double-blind, placebo-controlled, randomized controlled trial to be conducted in patients with both colorectal ACF and colorectal polyps scheduled for polypectomy. Eligible patients shall be recruited for the study and the number of ACF in the rectum counted at the baseline colonoscopy. Then, the participants shall be allocated randomly to either one of two groups, the EPA group and the placebo group. Patients in the EPA group shall receive oral 900-mg EPA capsules thrice daily (total daily dose, 2.7 g per day), and those in the placebo group shall receive oral placebo capsules thrice daily. After one month’s treatment with EPA/placebo, colonoscopic examination and polypectomy will be performed to evaluate the formation of ACF, and the cell-proliferative activity and cell-apoptotic activity in normal colorectal mucosa and colorectal polyps. Discussion This is the first study proposed to explore the effect of EPA against colorectal ACF formation in humans. This trial has been registered in the University hospital Medical Information Network (UMIN) Clinical Trials Registry as UMIN000008172.

Published
2012
Full Text
View/download PDF

20. SNP (–617C>A) in ARE-Like Loci of the NRF2 Gene: A New Biomarker for Prognosis of Lung Adenocarcinoma in Japanese Non-Smoking Women

Author

Okano, Yasuko, primary, Nezu, Uru, additional, Enokida, Yasuaki, additional, Lee, Ming Ta Michael, additional, Kinoshita, Hiroko, additional, Lezhava, Alexander, additional, Hayashizaki, Yoshihide, additional, Morita, Satoshi, additional, Taguri, Masataka, additional, Ichikawa, Yasushi, additional, Kaneko, Takeshi, additional, Natsumeda, Yutaka, additional, Yokose, Tomoyuki, additional, Nakayama, Haruhiko, additional, Miyagi, Yohei, additional, and Ishikawa, Toshihisa, additional

Published
2013
Full Text
View/download PDF

22. Increased oxidative stress and coenzyme Q10 deficiency in juvenile fibromyalgia: amelioration of hypercholesterolemia and fatigue by ubiquinol-10 supplementation

Author

Miyamae, Takako, primary, Seki, Manabu, additional, Naga, Tomoko, additional, Uchino, Shinya, additional, Asazuma, Haruki, additional, Yoshida, Takuma, additional, Iizuka, Yuki, additional, Kikuchi, Masako, additional, Imagawa, Tomoyuki, additional, Natsumeda, Yutaka, additional, Yokota, Shumpei, additional, and Yamamoto, Yorihiro, additional

Published
2013
Full Text
View/download PDF

23. Capsule-Endoscopic Findings of Ulcerative Colitis Patients

Author

Higurashi, Takuma, primary, Endo, Hiroki, additional, Yoneda, Masato, additional, Hosono, Kunihiro, additional, Sakai, Eiji, additional, Takahashi, Hirokazu, additional, Inamori, Masahiko, additional, Uchiyama, Shiori, additional, Kojima, Takuto, additional, Kawana, Kenichi, additional, Natsumeda, Yutaka, additional, Nagase, Hajime, additional, and Nakajima, Atsushi, additional

Published
2011
Full Text
View/download PDF

24. Pravastatin Potentiates Increases in Serum Adiponectin Concentration in Dyslipidemic Patients Receiving Thiazolidinedione: the DOLPHIN Study

Author

Nezu, Uru, primary, Tsunoda, Seishi, additional, Yoshimura, Hideki, additional, Kuwabara, Tetsuo, additional, Tomura, Shoken, additional, Seki, Yukio, additional, Kaneshiro, Mizuki, additional, Kamiyama, Hiroshi, additional, Harada, Yukina, additional, Shigematsu, Erina, additional, Aoki, Kazutaka, additional, Yamakawa, Tadashi, additional, Ohshige, Kenji, additional, Natsumeda, Yutaka, additional, and Terauchi, Yasuo, additional

Published
2010
Full Text
View/download PDF

26. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors

Author

Yamada, Yasuhide, primary, Tamura, Tomohide, additional, Yamamoto, Noboru, additional, Shimoyama, Tatsu, additional, Ueda, Yutaka, additional, Murakami, Haruyasu, additional, Kusaba, Hitoshi, additional, Kamiya, Yoshikazu, additional, Saka, Hideo, additional, Tanigawara, Yusuke, additional, McGovren, J. Patrick, additional, and Natsumeda, Yutaka, additional

Published
2005
Full Text
View/download PDF

34. Heterogeneity of the efficacy of the 23-valent pneumococcal polysaccharide vaccine caused by various underlying conditions of chronic pulmonary disease in older patients: prospective cohort study.

Author

Inoue, Satoshi, Watanuki, Yuji, Kaneko, Tetsuji, Sato, Takashi, Miyazawa, Naoki, Kaneko, Takeshi, Ishigatsubo, Yoshiaki, Morita, Satoshi, Natsumeda, Yutaka, and Mizushima, Shunsaku

Abstract

Objective: To determine the ideal conditions for use of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older outpatients with chronic pulmonary diseases. Design: Prospective cohort study. Participants: 1378 outpatients with chronic pulmonary diseases ≥60 years of age. Intervention: Participants were educated about PPV23, and those who responded affirmatively were vaccinated between August and November 2002. The participants who chose no intervention served as controls. The prevaccine period was defined as August 2001 to August 2002. Participants were followed for 2 years from December 2002 or until death. Main outcome measures: Events of interest included the first episode of bacterial (including pneumococcal) pulmonary infection (primary endpoint) and death of any cause (secondary endpoint). Results: Frequent episodes of pulmonary infection during the prevaccine period significantly decreased event-free survival during the 2-year observation period (p<0.001). Chronic respiratory failure was associated with a decreased event-free survival only when the pulmonary infection episode did not occur in the prevaccine period (p<0.001). No significant differences in event-free survival were observed between the vaccinated and unvaccinated group during analysis of the entire cohort. In the Cox proportional hazards regression model, event-free survival decreased significantly when pulmonary infection occurred in the prevaccine period. In the subgroup analysis, the first episode of bacterial pulmonary infection (but not death of any cause) was reduced significantly by PPV23 only in patients with chronic respiratory failure who had no episodes of pulmonary infection during the prevaccine period (p1/40.019). Conclusion: The efficacy of PPV23 against pulmonary infection and death of any cause might be unachievable if pulmonary infection occurs during the prevaccine period. PPV23 needs to be given to older patients with chronic pulmonary disease at an earlier time in which infectious complications in the lung have not yet occurred. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

36. Regulation of de novo and salvage pathways in chemotherapy

Author

Weber, George, primary, Nagai, Masami, additional, Natsumeda, Yutaka, additional, Ichikawa, Seiichi, additional, Nakamura, Hiroyuki, additional, Eble, John N., additional, Jayaram, Hiremagalur N., additional, Zhen, Weining, additional, Paulik, Edith, additional, Hoffman, Ronald, additional, and Tricot, Guido, additional

Published
1991
Full Text
View/download PDF

40. Enzymic programs of rat bone marrow and the impact of acivicin and tiazofurin

Author

Melissa A. Reardon, Jahangir Emrani, Szondy Susan, Noemi Prajda, Natsumeda Yutaka, Hashimoto Yasuko, George Weber, and Ikegami Tadashi

Subjects
Thymidine kinase activity, Ribonucleoside Diphosphate Reductase, Orotidine-5'-Phosphate Decarboxylase, Biochemistry, Ligases, chemistry.chemical_compound, IMP dehydrogenase activity, Bone Marrow, IMP dehydrogenase, Deoxycytidine Kinase, Ribavirin, Aspartate Carbamoyltransferase, Thymidine Monophosphate, medicine, Animals, Carbon-Nitrogen Ligases, Elméleti orvostudományok, Purine metabolism, Oxazoles, Acivicin, Hypoxanthine, Pharmacology, biology, Adenylosuccinate synthase, Isoxazoles, Thymidylate Synthase, Orvostudományok, Molecular biology, Rats, chemistry, biology.protein, Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing), Ribonucleosides, Tiazofurin, medicine.drug
Abstract

The in vivo actions of two antimetabolites, acivicin (NSC-163501) and tiazofurin (NSC-286193), were examined on the enzymic programs of rat bone marrow. From the bone marrow of the femurs, 100,000 g supernatant fractions were prepared; enzymic activities were measured by isotopic assays, and cellularity was determined. In the normal bone marrow, the specific activities of pyrimidine de novo synthetic enzymes, CDP reductase, dTMP synthase, CTP synthase, carbamoyl-phosphate synthase II (synthase II), orotidine 5'-phosphate decarboxylase and aspartate carbamoyltransferase, were 1, 2.7, 5, 10, 63 and 601 nmol/hr/mg protein, respectively, whereas those of the salvage enzymes, deoxycytidine, thymidine, cytidine and uridine kinases were 3, 43, 149, and 367 nmol/hr/mg protein, respectively. In purine biosynthesis, the activities of the de novo synthetic enzymes, IMP dehydrogenase, fonnylglycinamidine ribonucleotide (FGAM) synthase, GMP synthase, amidophosphoribosyitransferase (AT) and adenylosuccinate synthase were 16, 8, 107, 78 and 124 nmol/hr/mg protein, respectively, and those of the salvage enzymes, adenine, hypoxanthine and guanine phosphoribosyl-transferases, were 340, 407, and 1018 mol/hr/mg protein, respectively. The sequence of events was elucidated after a single i.p. injection of acivicin (5 mg/kg) or tiazofurin (200 mg/kg). Within 2hr after acivicin injection, CTP, GMP and FGAM synthases lost 85–90%, while AT and synthase II lost 50 and 80%, respectively, of their activities. The activities rose to near normal range by 72–96 hr. The bone marrow cellularity decreased, reaching a nadir at 24 and 48 hr, and returning to normal range by 72 and 92 hr; thymidine kinase activity followed a similar pattern. Tiazofurin injection depressed IMP dehydrogenase activity to 20% by 2 hr with a rebound to normal range by 48 and 72 hr. The cellularity decreased more slowly, reaching its lowest point at 24 hr and returning to normal range at 72 hr. For acivicin the marked depletion of the activities of the glutamine-utilizing enzymes and for tiazofurin that of IMP dehydrogenase might account, in part at least, for the bone marrow toxicity of these antimetabolites. Because of the presence in the bone marrow of high activities of purine and pyrimidine salvage enzymes, it should be possible to design methods utilizing nucleosides and nucleobases to protect the bone marrow from the action of antimetabolites.

Published
1988

Catalog

Books, media, physical & digital resources
See catalog results